Your browser doesn't support javascript.
Immunological Biomarkers of Fatal COVID-19: A Study of 868 Patients.
Martín-Sánchez, Esperanza; Garcés, Juan José; Maia, Catarina; Inogés, Susana; López-Díaz de Cerio, Ascensión; Carmona-Torre, Francisco; Marin-Oto, Marta; Alegre, Félix; Molano, Elvira; Fernandez-Alonso, Mirian; Perez, Cristina; Botta, Cirino; Zabaleta, Aintzane; Alcaide, Ana Belen; Landecho, Manuel F; Rua, Marta; Pérez-Warnisher, Teresa; Blanco, Laura; Sarvide, Sarai; Vilas-Zornoza, Amaia; Alignani, Diego; Moreno, Cristina; Pineda, Iñigo; Sogbe, Miguel; Argemi, Josepmaria; Paiva, Bruno; Yuste, José Ramón.
  • Martín-Sánchez E; Hematology Department, Clínica Universidad de Navarra, Pamplona, Spain.
  • Garcés JJ; Hemato-Oncology Department, Centro de Investigación Médica Aplicada (CIMA), Pamplona, Spain.
  • Maia C; Hemato-Oncology Department, Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain.
  • Inogés S; Centro de Investigación Biomédica en Red, Pamplona, Spain.
  • López-Díaz de Cerio A; Hematology Department, Clínica Universidad de Navarra, Pamplona, Spain.
  • Carmona-Torre F; Hemato-Oncology Department, Centro de Investigación Médica Aplicada (CIMA), Pamplona, Spain.
  • Marin-Oto M; Hemato-Oncology Department, Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain.
  • Alegre F; Centro de Investigación Biomédica en Red, Pamplona, Spain.
  • Molano E; Hematology Department, Clínica Universidad de Navarra, Pamplona, Spain.
  • Fernandez-Alonso M; Hemato-Oncology Department, Centro de Investigación Médica Aplicada (CIMA), Pamplona, Spain.
  • Perez C; Hemato-Oncology Department, Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain.
  • Botta C; Centro de Investigación Biomédica en Red, Pamplona, Spain.
  • Zabaleta A; Centro de Investigación Biomédica en Red, Pamplona, Spain.
  • Alcaide AB; Immunology and Immunotherapy Department, Clínica Universidad de Navarra, Pamplona, Spain.
  • Landecho MF; Hematology Service and Cell Therapy Area, Clínica Universidad de Navarra, Pamplona, Spain.
  • Rua M; Centro de Investigación Biomédica en Red, Pamplona, Spain.
  • Pérez-Warnisher T; Immunology and Immunotherapy Department, Clínica Universidad de Navarra, Pamplona, Spain.
  • Blanco L; Hematology Service and Cell Therapy Area, Clínica Universidad de Navarra, Pamplona, Spain.
  • Sarvide S; Internal Medicine Department, Clínica Universidad de Navarra, Pamplona, Spain.
  • Vilas-Zornoza A; Division of Infectious Diseases, Clínica Universidad de Navarra, Pamplona, Spain.
  • Alignani D; Immune and Infectious Inflammatory Diseases Research, Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain.
  • Moreno C; Neumology Department, Clínica Universidad de Navarra, Pamplona, Spain.
  • Pineda I; Internal Medicine Department, Clínica Universidad de Navarra, Pamplona, Spain.
  • Sogbe M; Internal Medicine Department, Clínica Universidad de Navarra, Madrid, Spain.
  • Argemi J; Immune and Infectious Inflammatory Diseases Research, Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain.
  • Paiva B; Microbiology Department, Clínica Universidad de Navarra, Pamplona, Spain.
  • Yuste JR; Hemato-Oncology Department, Centro de Investigación Médica Aplicada (CIMA), Pamplona, Spain.
Front Immunol ; 12: 659018, 2021.
Article in English | MEDLINE | ID: covidwho-1236672
ABSTRACT
Information on the immunopathobiology of coronavirus disease 2019 (COVID-19) is rapidly increasing; however, there remains a need to identify immune features predictive of fatal outcome. This large-scale study characterized immune responses to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection using multidimensional flow cytometry, with the aim of identifying high-risk immune biomarkers. Holistic and unbiased analyses of 17 immune cell-types were conducted on 1,075 peripheral blood samples obtained from 868 COVID-19 patients and on samples from 24 patients presenting with non-SARS-CoV-2 infections and 36 healthy donors. Immune profiles of COVID-19 patients were significantly different from those of age-matched healthy donors but generally similar to those of patients with non-SARS-CoV-2 infections. Unsupervised clustering analysis revealed three immunotypes during SARS-CoV-2 infection; immunotype 1 (14% of patients) was characterized by significantly lower percentages of all immune cell-types except neutrophils and circulating plasma cells, and was significantly associated with severe disease. Reduced B-cell percentage was most strongly associated with risk of death. On multivariate analysis incorporating age and comorbidities, B-cell and non-classical monocyte percentages were independent prognostic factors for survival in training (n=513) and validation (n=355) cohorts. Therefore, reduced percentages of B-cells and non-classical monocytes are high-risk immune biomarkers for risk-stratification of COVID-19 patients.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Type of study: Cohort study / Observational study / Prognostic study Limits: Adult / Aged / Female / Humans / Male / Middle aged / Young adult Language: English Journal: Front Immunol Year: 2021 Document Type: Article Affiliation country: Fimmu.2021.659018

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Type of study: Cohort study / Observational study / Prognostic study Limits: Adult / Aged / Female / Humans / Male / Middle aged / Young adult Language: English Journal: Front Immunol Year: 2021 Document Type: Article Affiliation country: Fimmu.2021.659018